{
    "eid": "2-s2.0-85110120875",
    "title": "Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial",
    "cover-date": "2021-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Endocrinology, Diabetes and Metabolism",
            "@code": "2712",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Reproductive Medicine",
            "@code": "2743",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Endocrinology",
            "@code": "1310",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Psychiatry and Mental Health",
            "@code": "2738",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Urology",
            "@code": "2748",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Androgen antagonists",
        "Cyproterone acetate",
        "Feminizing hormone therapy",
        "Gender dysphoria",
        "Spironolactone",
        "Transgender persons"
    ],
    "authors": [
        "Supanat Burinkul",
        "Krasean Panyakhamlerd",
        "Ammarin Suwan",
        "Punkavee Tuntiviriyapun",
        "Sorawit Wainipitapong"
    ],
    "citedby-count": 13,
    "ref-count": 41,
    "ref-list": [
        "Standards of care for the health of transsexual, transgender, and gender nonconforming people",
        "Experiences of transgender-related discrimination and implications for health: Results from the Virginia Transgender Health Initiative Study",
        "Gender confirmation surgery: Guiding principles",
        "Multidisciplinary care and the standards of care for transgender and gender nonconforming individuals",
        "Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism",
        "Hormonal treatment of transgender women with oral estradiol",
        "Efficacy and safety of pubertal induction using 17beta-estradiol in transgirls",
        "Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline",
        "Hormonal treatment strategies tailored to non-binary transgender individuals",
        "Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up",
        "The peripubertal gender-dysphoric child: puberty suppression and treatment paradigms",
        "Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone",
        "Effect of spironolactone on sex hormones in man",
        "A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule",
        "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study",
        "Spironolactone for the treatment of acne in women, a retrospective study of 110 patients",
        "Testosterone levels achieved by medically treated transgender women in a United States Endocrinology Clinic Cohort",
        "Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer",
        "A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria",
        "Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people",
        "Hepatotoxicity induced by cyproterone acetate: A report of three cases",
        "Differential effects of cyproterone acetate vs spironolactone on serum high-density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women",
        "Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy",
        "Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: A comparison of safety and effectiveness",
        "Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?",
        "Rates of hyperkalemia after publication of the randomized Aldactone evaluation study",
        "A critical evaluation of simple methods for the estimation of free testosterone in serum",
        "Prolactin levels do not rise among transgender women treated with estradiol and spironolactone",
        "Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment",
        "Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline",
        "Young adult psychological outcome after puberty suppression and gender reassignment",
        "Barriers to gender transition-related healthcare: Identifying underserved transgender adults in Massachusetts",
        "Experiences of and barriers to transition-related healthcare among Korean transgender adults: focus on gender identity disorder diagnosis, hormone therapy, and sex reassignment surgery",
        "Cross-sex hormone treatment in male-to-female transsexual persons reduces serum brain-derived neurotrophic factor (BDNF)",
        "Effects of cross-sex hormone treatment on transgender women and men",
        "Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist",
        "Body composition, volumetric and areal bone parameters in male-to-female transsexual persons",
        "Impact of cross-sex hormone therapy on bone mineral density and body composition in transwomen",
        "Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate",
        "Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European network for the investigation of gender incongruence",
        "Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Chulalongkorn University"
    ]
}